Latest Period
Q2 2026
Security Snapshot
Theravance Biopharma, Inc. - Ordinary Shares, $0.00001 Par Value (the "Ordinary Shares") (TBPH) Institutional Ownership
CUSIP: G8807B106
13F Institutional Holders and Ownership History from Q1 2014 to Q2 2026
Institutions Reporting
177
Shares (Excl. Options)
47,961,856
Price
$17.00
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary Shares, $0.00001 Par Value (the "Ordinary Shares")
- Symbol
- TBPH on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 47,961,856
- Total 13F value
- $815,293,289
- Portfolio coverage rank
- 0%
- Share change
- -2,025,506
- Value change
- -$32,740,002
- Number of holders
- 177
- Shares outstanding
- 52,046,621
- SEC-reported price per share
- $16.93
- Insider filing price
- $16.93
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- TBPH - Theravance Biopharma, Inc. - Ordinary Shares, $0.00001 Par Value (the "Ordinary Shares") is tracked under CUSIP G8807B106.
- 177 institutions reported positions in Q2 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 171 to 177 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $813,117,746 to $815,293,289.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 177 institutions filings for Q2 2026.
Security key
G8807B106
Latest holder period
Q2 2026
13F holders
177
13D/G owners
4
CIK / CUSIP context first
Open Q2 2026 holders
TBPH full holder history
Theravance Biopharma, Inc. SEC filings
Theravance Biopharma, Inc. company facts
Theravance Biopharma, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP G8807B106:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
TBPH
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Madison Avenue Partners, LP | 18% | $155,687,059 | 9,212,252 | Madison Avenue International LP | 30 Jun 2026 | |||
| Weiss Asset Management LP | 14% | $149,066,629 | 7,457,060 | Weiss Asset Management LP | 23 Mar 2026 | |||
| Newtyn Management, LLC | 6.7% | -20% | $58,037,828 | -$14,632,172 | 3,434,191 | -20% | Newtyn Management, LLC | 30 Jun 2026 |
| BlackRock, Inc. | 6.5% | $31,548,036 | 3,235,696 | BlackRock, Inc. | 31 Mar 2025 |
As of 30 Jun 2026, 177 institutional investors reported holding 47,961,856 shares of Theravance Biopharma, Inc. - Ordinary Shares, $0.00001 Par Value (the "Ordinary Shares") (TBPH). This represents 92% of the company’s total 52,046,621 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
81%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Madison Avenue Partners, LP | 18% | 9,212,252 | -3.1% | 6.7% | $156,608,284 |
| Weiss Asset Management LP | 14% | 7,457,060 | 0% | 1.4% | $126,770,020 |
| BlackRock, Inc. | 8.8% | 4,562,487 | +6.2% | 0% | $77,562,279 |
| Newtyn Management, LLC | 6.6% | 3,434,191 | -29% | 7.3% | $58,381,247 |
| Irenic Capital Management LP | 5.3% | 2,760,948 | 0% | 3.4% | $46,936,116 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.4% | 1,771,493 | -0.69% | 0% | $30,115,381 |
| STATE STREET CORP | 2.6% | 1,328,584 | +2.4% | 0% | $22,585,928 |
| TWO SIGMA INVESTMENTS, LP | 2.4% | 1,225,587 | -2.6% | 0.02% | $20,834,979 |
| D. E. Shaw & Co., Inc. | 2.3% | 1,185,390 | +24% | 0.01% | $20,151,630 |
| ACADIAN ASSET MANAGEMENT LLC | 2.3% | 1,174,910 | -8% | 0.02% | $19,963,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.1% | 1,117,895 | -1.7% | 0% | $19,006,198 |
| DIMENSIONAL FUND ADVISORS LP | 2% | 1,043,051 | +6% | 0% | $17,732,125 |
| MACKENZIE FINANCIAL CORP | 1.9% | 985,848 | +296% | 0.02% | $16,759,416 |
| MORGAN STANLEY | 1.4% | 705,201 | +38% | 0% | $11,988,417 |
| Oasis Management Co Ltd. | 1.1% | 583,490 | 0% | 1.1% | $9,919,330 |
| CITADEL ADVISORS LLC | 0.97% | 506,668 | +489% | 0% | $8,613,356 |
| UBS Group AG | 0.94% | 488,309 | -36% | 0% | $8,301,253 |
| Qube Research & Technologies Ltd | 0.83% | 429,813 | +48% | 0.01% | $7,306,821 |
| NORTHERN TRUST CORP | 0.78% | 404,356 | +9.1% | 0% | $6,874,052 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.76% | 394,158 | -1.6% | 0% | $6,700,686 |
| Jupiter Topco LLC | 0.74% | 387,493 | 0% | 0% | $6,587,485 |
| GOLDMAN SACHS GROUP INC | 0.65% | 339,960 | -18% | 0% | $5,779,320 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.62% | 321,154 | +3.4% | 0% | $5,459,618 |
| GLAZER CAPITAL, LLC | 0.58% | 301,834 | 0.13% | $5,131,000 | |
| VANGUARD FIDUCIARY TRUST CO | 0.52% | 272,234 | +3.9% | 0% | $4,627,978 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
50
Latest
Q2 2026
Rows shown
1-25 of 50
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 47,961,856 | $815,293,289 | -$32,740,002 | $17.00 | 177 |
| 2026 Q1 | 50,097,801 | $813,117,746 | +$3,344,085 | $16.23 | 171 |
| 2025 Q4 | 49,596,822 | $927,239,298 | +$22,675,473 | $18.71 | 168 |
| 2025 Q3 | 48,375,344 | $706,279,654 | +$36,991,609 | $14.60 | 159 |
| 2025 Q2 | 46,436,015 | $512,193,131 | +$17,041,767 | $11.03 | 134 |
| 2025 Q1 | 44,895,013 | $400,910,124 | +$805,783 | $8.93 | 130 |
| 2024 Q4 | 44,887,720 | $422,397,233 | -$6,899,094 | $9.41 | 128 |
| 2024 Q3 | 45,764,660 | $368,891,703 | -$13,728,533 | $8.06 | 118 |
| 2024 Q2 | 47,101,751 | $399,477,630 | -$8,156,185 | $8.48 | 129 |
| 2024 Q1 | 47,958,440 | $430,313,409 | -$10,017,643 | $8.97 | 119 |
| 2023 Q4 | 48,815,898 | $548,690,907 | -$21,251,604 | $11.24 | 116 |
| 2023 Q3 | 50,811,645 | $438,505,371 | -$20,825,244 | $8.63 | 113 |
| 2023 Q2 | 52,784,275 | $546,345,758 | -$76,354,796 | $10.35 | 117 |
| 2023 Q1 | 60,151,070 | $652,600,279 | -$20,647,357 | $10.85 | 112 |
| 2022 Q4 | 62,093,388 | $696,433,955 | -$41,903,451 | $11.22 | 118 |
| 2022 Q3 | 64,074,481 | $649,741,089 | +$1,849,322 | $10.14 | 114 |
| 2022 Q2 | 64,209,180 | $581,714,921 | +$11,702,533 | $9.06 | 106 |
| 2022 Q1 | 62,986,284 | $602,166,380 | +$31,622,746 | $9.56 | 114 |
| 2021 Q4 | 59,337,727 | $655,471,603 | -$7,845,717 | $11.05 | 109 |
| 2021 Q3 | 60,653,808 | $448,777,384 | -$37,107,153 | $7.40 | 111 |
| 2021 Q2 | 60,758,215 | $882,854,201 | +$106,504,226 | $14.52 | 101 |
| 2021 Q1 | 53,537,579 | $1,092,709,410 | +$7,301,237 | $20.41 | 104 |
| 2020 Q4 | 53,239,274 | $946,045,510 | +$17,733,590 | $17.77 | 103 |
| 2020 Q3 | 52,459,569 | $775,625,748 | -$4,497,125 | $14.78 | 113 |
| 2020 Q2 | 52,961,450 | $1,111,646,885 | -$95,003,651 | $20.99 | 121 |